Sugi Predict

Sugi Predict / Compounds / Tetrahydrofuran

Tetrahydrofuran

Tetrahydrofuran

SCHEMBL3544589

C1CCOC1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60
▸ ESR1 P03372 2/20 0.46
▸ ESR2 Q92731 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ CRHBP P24387 2/20 0.37
▸ CRHR2 Q13324 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ GAA P10253 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ DRD1 P21728 2/20 0.36
▸ PKM P14618 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ FKBP1A P62942 1/20 0.32
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrofuran SCHEMBL4256459 0.98 CYP3A4 (0.57) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL1007230 0.98 CYP3A4 (0.57) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL2014438 0.98 CYP3A4 (0.57) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL28163050 0.91 CYP3A4 (0.50) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL28244884 0.91 CYP3A4 (0.50) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL28244765 0.91 CYP3A4 (0.50) CYP3A4TDP1ESR1ESR2ALDH1A1
Dioxane SCHEMBL27471817 0.90 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2LMNA
Oxirane SCHEMBL29388114 0.87 CYP3A4 (0.71) CYP3A4TDP1ESR1ESR2LMNA
Tetrahydrofuran SCHEMBL28355034 0.81 ALDH1A1 (0.36) CYP3A4TDP1ALDH1A1LMNASMN1; SMN2
Tetrahydrofuran SCHEMBL28140268 0.81 ESR1 (0.50) CYP3A4TDP1ESR1ESR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113754700-A Preparation method of bis (triphenylphosphine) palladium dichloride 浙江微通催化新材料有限公司 2021-12-07 — — CN disclosed
CN-109988125-A The preparation method of a kind of novel benzophenone amine compounds and the application in oncotherapy 河南省锐达医药科技有限公司 2019-07-09 — — CN disclosed
CN-109952303-A TYK2 inhibitor and application thereof 林伯士拉克许米公司 2019-06-28 — — CN disclosed
CN-108794370-A A kind of preparation method for drawing sieve to replace Buddhist nun's intermediate 上海弈柯莱生物医药科技有限公司 2018-11-13 — — CN disclosed
CN-207685173-U A kind of system preparing propylene acid low carbon alcohol ester with coal pyrolysis gas 北京华福工程有限公司 2018-08-03 — — CN disclosed
CN-104603327-B Manufacture method, film formation raw material and the molybdenum imide compound of film containing molybdenum 株式会社艾迪科 2017-12-01 — — CN disclosed
CN-106986872-A Bromine domain inhibitor 艾伯维公司 2017-07-28 — — CN disclosed
CN-104119312-B A kind of synthetic method of 25-hydroxyvitamin D3 安徽智新生化有限公司 2016-08-24 — — CN disclosed
CN-102942603-B New aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-01-20 — — CN disclosed
CN-102942603-A Novel aminoglycoside antibiotics MEIJI SEIKA KAISHA (JP) 2013-02-27 — — CN disclosed
US-7825147-B2 Inhibitors of phosphodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2010-11-02 — — US disclosed
CN-101495493-A Novel aminoglycoside antibiotics MEIJI SEIKA KAISHA (JP) 2009-07-29 — — CN disclosed
CN-101463002-A Dihydroxy-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivative and preparation SHANGHAI YAOMING KANGDE PHARMA (CN) 2009-06-24 — — CN disclosed
CN-101094847-A Aryloxy-substituted benzimidazole derivatives BANYU PHARMA CO LTD (JP) 2007-12-26 — — CN disclosed
CN-1835914-A New benzamides as PPAR[upsilon] modulators S A L V A T LAB SA (ES) 2006-09-20 — — CN disclosed
EP-1663999-A2 INHIBITORS OF PHOSPHODIESTERASE TYPE-IV RANBAXY LABORATORIES, LTD. (IN) 2006-06-07 — — EP disclosed
CN-1219753-C Oxygenated esters of 4-iodophenylamino phenoxy hydroxamic acid WARNER LAMBERT CO (US) 2005-09-21 — — CN disclosed
US-20050075383-A1 Inhibitors of phophodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 — — US disclosed
WO-2005021515-A2 INHIBITORS OF PHOSPHODIESTERASE TYPE-IV RANBAXY LABORATORIES LIMITED (IN) 2005-03-10 — — WO disclosed
CN-1446197-A Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids WARNER LAMBERT CO (US) 2003-10-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075383-A1 Inhibitors of phophodiesterase type-IV PDE7A, PDE4A, PDE4B CYP3A4 379/4885TDP1 1034/4885ESR1 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.